Literature DB >> 6652348

Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine.

P Cervoni, H E Herzlinger, F M Lai, T K Tanikella.   

Abstract

The effects of (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine (octadecyl-AGPC) were studied in three types of aortic vascular smooth muscle preparations, namely, strips, rubbed and unrubbed rings, and an atrial preparation in normotensive rats. In the resting tension state, octadecyl-AGPC did not elicit significant contractions in either rubbed or unrubbed ring preparations at concentrations lower than 1 X 10(-4) M. However, at a concentration of 3 X 10(-4) M, octadecyl-AGPC markedly contracted both types of ring preparations. This contractile response was partially antagonized by pretreatment with reserpine and completely blocked by phentolamine (1 X 10(-6) M). In preparations contracted with noradrenaline (NA), octadecyl-AGPC elicited biphasic responses in intact ring preparations; an initial relaxation followed by contraction. Octadecyl-AGPC induced only a slight contraction in strips and a slight relaxation in the rubbed ring preparation. Octadecyl-AGPC did not elicit any significant effect on chronotropy or inotropy at concentrations up to 3 X 10(-5) M. When the concentration was 1 X 10(-4) M, octadecyl-AGPC produced significant positive chronotropic and inotropic effects on spontaneously beating right and electrically driven left atrial preparations, respectively. Both effects were blocked by propranolol (5 X 10(-8) M); reserpine pretreatment antagonized only the chronotropic response. In [3H]-dihydroalprenolol [( 3H]-DHA) binding studies, octadecyl-AGPC had a Kd of 427.85 microM and thus was much less potent than isoprenaline (Kd = 465.10 nM) or propranolol (Kd = 4.4 nM) in displacing [3H]-DHA in rat cardiac membrane preparations. 6 In conclusion, relaxation and contraction induced by octadecyl-AGPC in aortic preparations is an indirect rather than a direct effect. An unknown factor released from endothelial cells is responsible for aortic smooth muscle relaxation by octadecyl-AGPC while released NA appears to be responsible for aortic vascular contraction and for the positive chronotropic and inotropic effects in the atrial preparations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652348      PMCID: PMC2044904          DOI: 10.1111/j.1476-5381.1983.tb10003.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs.

Authors:  R F FURCHGOTT; S BHADRAKOM
Journal:  J Pharmacol Exp Ther       Date:  1953-06       Impact factor: 4.030

Review 2.  Antihypertensive functions of the kidney: Arthur C. Corcoran memorial lecture.

Authors:  E E Muirhead
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

3.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

4.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

5.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

6.  Disposition of catecholamines in cardiovascular tissues of aorta coarcted hypertensive rats.

Authors:  B M Goldstein; F M Lai; H Herzlinger; P Cervoni
Journal:  Life Sci       Date:  1982-10-11       Impact factor: 5.037

7.  Cardiac beta-adrenoceptors during normal growth of male and female rats.

Authors:  S P Baker; L T Potter
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

8.  Hypotensive and vasodilatory activity of (+/-) 1-o-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat.

Authors:  F M Lai; C A Shepherd; P Cervoni; A Wissner
Journal:  Life Sci       Date:  1983-03-07       Impact factor: 5.037

9.  A comparison of cardiac reactivity and beta-adrenoceptor number and affinity between aorta-coarcted hypertensive and normotensive rats.

Authors:  P Cervoni; H Herzlinger; F M Lai; T Tanikella
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

  9 in total
  6 in total

1.  Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta.

Authors:  H Moritoki; T Hisayama; S Takeuchi; H Miyano; W Kondoh
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 2.  Cardiovascular effects of platelet-activating factor.

Authors:  R E Goldstein; G Z Feuerstein; L M Bradley; J J Stambouly; F R Laurindo; N J Davenport
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes.

Authors:  G M Wahler; D E Coyle; N Sperelakis
Journal:  Mol Cell Biochem       Date:  1990-03-05       Impact factor: 3.396

4.  Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.

Authors:  P J Piper; A G Stewart
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

5.  Electrophysiological effects of acetyl glyceryl ether phosphorylcholine on cardiac tissues: comparison with lysophosphatidylcholine and long chain acyl carnitine.

Authors:  H Nakaya; N Tohse
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

6.  Effect of platelet-activating factor (PAF) on sodium calcium exchange in cardiac sarcolemmal vesicles.

Authors:  H P Meng; M J Kutryk; G N Pierce
Journal:  Mol Cell Biochem       Date:  1990-01-18       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.